Table 5.
Characteristics of patients in different remission states at 6 and 12 months.
| SJC28 near-remission | PGA near-remission | Remission | Non-remission | |
|---|---|---|---|---|
| 6 months | n = 77 | n = 48 | n = 69 | n = 329 |
| Disease activity | ||||
| SJC28, mean (SD) | 3.2 (1.5)* | 0.5 (0.5)*§ | 0.5 (0.6)*# | 4.3 (3.1)*§ |
| TJC28, mean (SD) | 0.2 (0.4)* | 0.3 (0.6)§ | 0.1 (0.4)§# | 4 (4.9)*§# |
| PROs | ||||
| VAS pain, mean (SD) (0–100) | 6.9 (13.7)* | 29.6 (23.6)*§ | 3.9 (7.7)*§# | 35.9 (25.4)*§# |
| PGA, mean (SD) (0–10) | 0.3 (0.4)* | 3.4 (2.3)*§ | 0.2 (0.3)§# | 3.5 (2.)*# |
| Laboratory | ||||
| ESR, mm/1 h, mean (SD) | 15.8 (9.9)* | 16.6 (11.7)§ | 13.5 (9.9)*§# | 21.6 (15.9)*§# |
| CRP, mg/dl, mean (SD) | 0.27 (0.23)* | 0.35 (0.25)*# | 0.25 (0.23)*# | 0.78 (1.79)*# |
| 12 months | n = 76 | n = 48 | n = 91 | n = 289 |
| Disease activity | ||||
| SJC28, mean (SD) | 2.9 (1.5)* | 0.6 (0.5)*§ | 0.4 (0.5)*§# | 3.7 (2.5)*§# |
| TJC28, mean (SD) | 0.2 (0.4)* | 0.3 (0.4)§ | 0.1 (0.3)*§# | 3.8 (5)*§# |
| PROs | ||||
| VAS pain, mean (SD) (0–100) | 5.8 (8.8)* | 35.2 (24.7)*§ | 6 (10.3)§# | 38.3 (26.5)*§# |
| PGA, mean (SD) (0–10) | 0.2 (0.3)* | 3.9 (2.5)*§ | 0.3 (0.4)§# | 3.5 (2.4)*# |
| Laboratory | ||||
| ESR, mm/1 h, mean (SD) | 17.9 (12.7)* | 18.7 (17.1)§ | 15.6 (11.2)*§# | 21.6 (17)*§# |
| CRP, mg/dl, mean (SD) | 0.31 (0.50)* | 0.36 (0.26)*§ | 0.26 (0.22)*§# | 0.82 (2.03)*§# |
*,§,#
p < 0.05 based on ANOVA analysis of variance with Student–Newman–Keuls test for all pairwise comparisons.
*
SJC28 near-remission versus PGA near-remission, remission and non-remission.
§
PGA near-remission versus remission and non-remission.
#
Remission versus non-remission.
CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; PGA, patient global assessment; PhGA, physician global assessment of disease activity; PROs, patient reported outcomes; SD, standard deviation; SJC28, swollen joint count on 28 joints; TJC28, tender joint count on 28 joints; VAS, visual analogue scale.